Fierce Pharma

JUNE 8, 2023

Fierce Pharma Asia—Eisai and Biogen's Leqembi progress; AZ and Daiichi's Enhertu data; Samsung Biologics' manufacturing deal zbecker Thu, 06/08/2023 - 19:34

Manufacturing 244

Manufacturing Pharma 244

Fierce Pharma

MAY 26, 2023

Fierce Pharma Asia—Carvykti's EU filing; Thermo Fisher's Singapore expansion; Celltrion's Humira biosim nod aliu Fri, 05/26/2023 - 08:43

Pharma 232

Pharma 232

Fierce Pharma

APRIL 6, 2023

Fierce Pharma Asia—BioNTech's ADC deal; Sanofi's potential consumer cut; Takeda's latest celiac play aliu Thu, 04/06/2023 - 15:39

Pharma 245

Pharma 245

Fierce Pharma

MARCH 23, 2023

Fierce Pharma Asia—Takeda's $4B psoriasis data; Biohaven's neurology bet; Pfizer and Astellas' Xtandi wins aliu Thu, 03/23/2023 - 18:29

Pharma 242

Pharma 242

Fierce Pharma

JANUARY 26, 2023

Fierce Pharma Asia—Takeda's cancer deal; BeiGene's Brukinsa nod; Astellas' gene therapy reprieve aliu Thu, 01/26/2023 - 14:58

Pharma 230

Pharma 230

Fierce Pharma

DECEMBER 2, 2022

Fierce Pharma Asia—Eisai's lecanemab Alzheimer's debate; BeiGene's Imbruvica showdown; Shionogi's COVID drug nod. Fri, 12/02/2022 - 08:55.

Pharma 239

Pharma 239

Fierce Pharma

MARCH 2, 2023

Fierce Pharma Asia—Samsung's deal with Pfizer; Olympus' and Dr. Reddy's M&A moves; BeiGene's growth aliu Thu, 03/02/2023 - 15:58

Pharma 245

Pharma 245

Fierce Pharma

NOVEMBER 18, 2022

Fierce Pharma Asia—BioNTech, GSK grow in Singapore; Astellas' stomach cancer win; Daiichi's mRNA vaccine readout. Fri, 11/18/2022 - 09:44.

Pharma 246

Pharma 246

Fierce Pharma

FEBRUARY 2, 2023

Fierce Pharma Asia—J&J, Legend's CAR-T win; Sanofi's India job cuts; BeiGene, Novartis' PD-1 delay aliu Thu, 02/02/2023 - 15:58

Pharma 259

Pharma 259

Fierce Pharma

JANUARY 6, 2023

Fierce Pharma Asia—Eisai’s Alzheimer’s trial deaths; Moderna’s first M&A deal; GSK, WuXi's bispecific pact. Fri, 01/06/2023 - 10:36.

Pharma 229

Pharma 229

Fierce Pharma

APRIL 27, 2023

Fierce Pharma Asia—Daiichi's leukemia delay, Enhertu gains; Glenmark's settlement aliu Thu, 04/27/2023 - 22:47

Pharma 130

Pharma 130

Fierce Pharma

MAY 11, 2023

Fierce Pharma Asia—Roche, Eisai's HER2 deals; Takeda's layoffs in the US aliu Thu, 05/11/2023 - 15:14

Pharma 146

Pharma 146

Fierce Pharma

FEBRUARY 23, 2023

Fierce Pharma Asia—Eisai's Leqembi hurdle; AZ's cancer deal; and Mitsubishi's royalty win aliu Thu, 02/23/2023 - 15:26

Pharma 146

Pharma 146

Fierce Pharma

APRIL 13, 2023

Fierce Pharma Asia—Takeda's gene therapy pivot and pay-for-delay lawsuit; Astellas' write-offs aliu Thu, 04/13/2023 - 16:07

Pharma 146

Pharma 146

Fierce Pharma

FEBRUARY 10, 2023

Fierce Pharma Asia—Astellas' new CEO; Eisai's Alzheimer’s launch; Mitsubishi's Medicago closure aliu Fri, 02/10/2023 - 08:10

Pharma 130

Pharma 130

Fierce Pharma

MARCH 16, 2023

Fierce Pharma Asia—Sun's price-fixing settlement; Eisai's coverage win; AstraZeneca's India layoffs aliu Thu, 03/16/2023 - 14:52

Pharma 130

Pharma 130

Fierce Pharma

MARCH 9, 2023

Fierce Pharma Asia—Leqembi's priority review; Enhertu's broad trial win; Cipla's FDA censure aliu Thu, 03/09/2023 - 15:27

Pharma 130

Pharma FDA 130

Fierce Pharma

FEBRUARY 16, 2023

Fierce Pharma Asia—Takeda's trial win, Biogen's pipeline pivot and Astellas' Super Bowl debut aliu Thu, 02/16/2023 - 15:08

Pharma 130

Pharma 130

Fierce Pharma

JANUARY 12, 2023

Fierce Pharma Asia—Eisai's Leqembi nod; 2 Astellas licensing deals; Samsung's ADC plan. Fri, 01/13/2023 - 00:30.

Pharma 130

Pharma 130

Fierce Pharma

MAY 4, 2023

Fierce Pharma Asia—Astellas' eye drug buy; J&J's latest CAR-T deal; Sun's clinical hold aliu Thu, 05/04/2023 - 17:10

Pharma 130

Pharma 130

Fierce Pharma

DECEMBER 9, 2022

Fierce Pharma Asia—MEI and Kyowa Kirin’s PI3K woes; Takeda’s dengue nod, Daiichii Sankyo’s Enhertu positivity. esagonowsky. Fri, 12/09/2022 - 10:43.

Pharma 130

Pharma 130

Fierce Pharma

NOVEMBER 10, 2022

Fierce Pharma Asia—German CEOs visit China; Sanofi, Insilico's $1.2B pact; Sumitomo's job cuts. Thu, 11/10/2022 - 16:53.

Pharma 130

Pharma 130

Fierce Pharma

MARCH 15, 2024

WuXi AppTec left the Biotechnology Industry Organization amid increasing pressure on the trade group stemming from a draft U.S. bill targeting certain Chinese biotechs. WuXi AppTec left BIO amid alleged biosecurity concerns and as U.S. lawmakers target certain Chinese biotechs.

FDA 246

FDA Pharma Manufacturing Patients 246

Fierce Pharma

APRIL 11, 2024

Geopolitical tensions are casting uncertainties over cross-border biotech deals. Geopolitical tensions are casting uncertainties over cross-border biotech deals. Johnson & Johnson and Legend Biotech's Carvykti, plus AstraZeneca and Daiichi Sankyo's Enhertu, secured new FDA approvals.

Pharma 215

Pharma FDA 215

Fierce Pharma

DECEMBER 15, 2022

Fierce Pharma Asia—Gracell's CAR-T wows, Takeda puts down $4B on Nimbus' TYK2 inhibitor, Bio Farma strikes Merck deal. Thu, 12/15/2022 - 20:11.

Pharma 130

Pharma 130

PM360

JULY 18, 2022

FINN Partners , an independent marketing and communications agency, is expanding its global footprint even further with the addition of SPAG , a leading, Asia-headquartered, health-sector communications and marketing firm with offices in Bangalore, Delhi, Indonesia, Malaysia, Mumbai, the Philippines, and Singapore.

Biopharma 96

Biopharma Management Leads Marketing 96

Fierce Pharma

MARCH 27, 2024

. | As pharma firms increasingly favor distribution pacts rather than relying on local subsidiaries to market their drugs, French major Sanofi has enlisted local companies to enhance the profile of its medicines across South and East Asia.

Distribution 295

Distribution Pharma Medicine Marketing 295

Fierce Pharma

JANUARY 18, 2024

Roche's TIGIT antibody has posted a positive phase 3 result that probably won't lead anywhere. In a win for Daiichi Sankyo, a U.S. agency has invalidated a Seagen patent. Roche's TIGIT antibody has posted a positive phase 3 result that probably won't lead anywhere. In a win for Daiichi Sankyo, a U.S.

Pharma 253

Pharma Leads 253

Fierce Pharma

AUGUST 31, 2023

Generics to Takeda's blockbuster ADHD drug Vyvanse are now approved in the U.S. Merck and Eisai's Keytruda-Lenvima combo failed in another pivotal trial. Generics to Takeda's blockbuster ADHD drug Vyvanse are now approved in the U.S. Merck and Eisai's Keytruda-Lenvima combo failed in another pivotal trial.

Pharma 244

Pharma 244

Fierce Pharma

APRIL 25, 2024

Novartis has started cutting ties with Chinese contractors amid a potential threat from the BIOSECURE Act. Novartis has started cutting ties with Chinese contractors amid a potential threat from the BIOSECURE Act. A depression drug candidate that Neurocrine licensed from Takeda succeeded in a phase 2 trial.

Pharma 130

Pharma 130

Fierce Pharma

MARCH 21, 2024

Three large pharma companies plan to expand their manufacturing footprints. Kyowa Kirin’s $4.25 million gene therapy set a new world pricing record. Three large pharma companies plan to expand their manufacturing footprints. Kyowa Kirin’s $4.25 million gene therapy set a new world pricing record.

Pharma 252

Pharma Manufacturing FDA 252

Fierce Pharma

APRIL 19, 2024

Medicare's spending projection on the Alzheimer's drug Leqembi is way higher than Eisai's own estimates. Takeda signed an immuno-oncology deal potentially worth more than $1.2 Medicare's spending projection on the Alzheimer's drug Leqembi is way higher than Eisai's own estimates. billion.

Pharma 130

Pharma 130

Fierce Pharma

MARCH 7, 2024

In separate updates from Japanese drugmakers, Eisai presented new projections for its Biogen-partnered Alzheimer's disease med Leqmebi, while Sumitomo Pharma initiated a round of layoffs | Eisai presented updated projections for Alzheimer's disease drug Leqembi. Sumitomo Pharma initiated a round of layoffs in the U.S.

Pharma 130

Pharma 130

Fierce Pharma

DECEMBER 7, 2023

WuXi Biologics' gloomy business update triggered a stock market avalanche. Daiichi Sankyo and Novartis reached a $182 million settlement on their BRAF drug patent dispute. WuXi Biologics' gloomy business update triggered a stock market avalanche.

Pharma 237

Pharma Marketing 237

Fierce Pharma

NOVEMBER 16, 2023

Novartis inked a solid tumor CAR-T deal with Legend Biotech. Novartis inked a solid tumor CAR-T deal with Legend Biotech. Astellas is buying a biotech, working to understand deaths in its gene therapy trial and partnering up to drive drug discovery. Ajinomoto will buy a gene therapy CDMO. And more.

Pharma 246

Pharma 246

Fierce Pharma

OCTOBER 12, 2023

GSK has tapped Chongqing Zhifei to distribute Shingrix in China. BioNTech in-licensed a HER3 antibody-drug conjugate from Chinese company MediLink Therapeutics. | GSK has tapped Chongqing Zhifei to distribute Shingrix in China. BioNTech in-licensed a HER3 antibody-drug conjugate from Chinese company MediLink Therapeutics.

Distribution 257

Distribution Pharma FDA 257

Fierce Pharma

NOVEMBER 9, 2023

AstraZeneca licensed an oral GLP-1 agonist from China's Eccogene. Takeda won FDA approval for the Hutchmed-developed colorectal cancer drug Fruzaqla. AstraZeneca licensed an oral GLP-1 agonist from China's Eccogene. Takeda won FDA approval for Hutchmed-developed colorectal cancer drug Fruzaqla.

FDA 242

FDA Pharma 242